Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SAR3419 in relapsed or refractory acute lymphoblastic leukemia
2012-002961-36Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coltuximab ravtansine in acute lymphoblastic leukemia (ALL) and Burkitt lymphoma (BL), sponsored by Sanofi. Primary endpoint: Objective response rate. Started Sep 2012; status: completed.
02
Drugs
coltuximab ravtansine
03
Conditions
acute lymphoblastic leukemia (ALL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2012-002961-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002961-36.